IDXX vs ILMN
Idexx Laboratories and Illumina, Inc., both Healthcare
Idexx Laboratories is the larger company at $44B against $25B. On trailing earnings IDXX is the cheaper of the two at a P/E of 38.9 against 42.0, a gap that is only a bargain if the two are growing at similar rates. Over the past year ILMN returned +136% against -11% for IDXX. Ryufin's sector-relative Smart Score puts IDXX ahead, 9/10 against 7/10.
| Figure | IDXX | ILMN |
|---|---|---|
| Last close | $553 | $225 |
| Market cap | $44B | $25B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 38.9 | 42.0 |
| 1-year return | -11% | +136% |
| 5-year return | -18% | -53% |
| Ryufin Smart Scoresector-relative, 1–10 | 9/10 | 7/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Idexx Laboratories
Revenue of $1.2B in Q2 2026, net income $338M. Its largest reported line is Vet Lab Consumables, 36% of the disclosed total.
Illumina, Inc.
Revenue of $1.2B in Q2 2026, net income $207M. Its largest reported line is United States And Canada, 54% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.